Colorectal cancer has become one of the most common types of cancer worldwide; it is the third most common cancer in men and the second most common cancer in women, with more than 1.2 million new cases and approximately 600 000 deaths each year. [1] [2] [3] From stage I to stage IV, the 5-year survival rate sharply decreases from 93.2% to 8.1%, so early diagnosis and standardization of treatment have become the key to improve the 5-year survival rate of CRC. 4 Therefore, more studies are needed to discover new effective diagnostic and prognostic biomarkers. Liu and Chen contribute equally to this study. Nuclear factor I/B (NFIB) is a widely studied transcription factor that participates in tumor progression; nevertheless, studies on NFIB in colorectal cancer (CRC) are limited. In our study, Western blot and RT-PCR analyses showed that NFIB was overex- 
In recent years, a growing number of studies have reported that NFIB plays an important role in embryonic development, maintenance of stem cell activity, regulation of cell differentiation and tumor-related functions. Wu et al 5 discovered that NFIB could promote cell migration in non-small cell lung cancer. miR-1224 was reported to impair proliferation and enhance apoptosis by repressing NFIB expression in hepatocytes upon ischemiareperfusion in vivo and in vitro. 6 Another study showed that NFIB could promote dynamic changes in the chromatin state of melanoma cells to facilitate migration, invasion and metastasis.
However, other studies report that NFIB serve as an oncogene in small cell lung cancer, melanoma and triple negative breast cancer, while NFIB inhibits tumor development and progression in glioma, glioblastoma and osteosarcoma. 7 Nevertheless, studies of NFIB in CRC are rare, and the biological function of NFIB in CRC is still unclear.
The Akt pathway plays a key role in cell proliferation, apoptosis, drug resistance and differentiation. 8 NFIB also has been reported to bind to the EZH2 promoter and promote EZH2 expression, 9 which can activate the PI3K/AKT pathway. 10 Wu et al 11 demonstrates that NFIB can activate the Akt/Stat3 signaling pathway. Therefore, we hypothesized that the Akt pathway may be involved in tumor progression caused by NFIB overexpression.
In our study, we discovered that NFIB promoted cell proliferation and 5-FU resistance by activating the Akt signaling pathway and facilitated migration and EMT by upregulating snail expression.
F I G U R E 1 Bioinformatic analysis of nuclear factor I/B (NFIB) expression in colorectal cancer (CRC).
A-H, Oncomine databases including 8 data-sets showed that NFIB was overexpressed in various types of CRC tissues. The NFIB expression profile was downloaded from TCGA website and analyzed by ROC curves. I, NFIB could distinguish CRC tissues and noncancerous tissues by ROC curves. NFIB expression in subgroups of CRC patients was analyzed by ROC curves: J, N0 vs N1+N2. K, Stage I+Stage II vs Stage III+Stage IV
| MATERIAL S AND ME THODS

| Bioinformatic analysis
The NFIB expression data were downloaded from TCGA website (https://xenabrowser.net/heatmap/) and the Oncomine Cancer
Microarray database (https://www.oncomine.org/resource/login. html); the data included age, gender, and TNM stage. Receiver operating characteristic (ROC) curve analysis was performed using GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA , USA).
| CRC tissue samples
Fifty four pairs of cancer tissues and adjacent normal tissues were collected from CRC radical surgery at the Wuhan Union Hospital between 2014 and 2017. All samples were from CRC patients without any chemoradiotherapy before surgery. The samples were divided into two parts: one part was snap-frozen in liquid nitrogen for further protein analysis, and the other part was fixed with formalin for immunohistochemistry (IHC) assays. All samples for our study were collected after signed informed consent from the patients. Our study was approved by the Human Research Ethics Committee of Huazhong University of Science and Technology.
| Cell culture and reagents
The normal human colon epithelium cell line FHC was cultured in DMEM/F12 (HyClone, Logan, UT, USA). The CRC cell lines DLDI and SW480 were maintained with RPMI1640 (HyClone), while HCT116
was grown in McCoy's 5A (HyClone), SW620 in DMEM/L15 (HyClone), 
| Western blotting assays
Cells and tissues were treated with cold RIPA buffer with PMSF (Sigma) and phosphorylase inhibitors (Beyotime). Protein samples were separated by SDS-PAGE gels and transferred onto PVDF membranes. The membranes were incubated with primary antibodies. Image J (National Institutes of Health, Bethesda, MD, USA) was used to measure the band density.
| Cell growth assay (CCK8 assay and EDU assay)
Cells ( and 72 hours, CCK8 assays were carried out to determine cell growth according to the manufacturer's protocol 12 . The EDU assay was carried out using a Cell-Light™ EDU Apollo ® 488 In
Vitro Flow Cytometry Kit according to the manufacturer's protocol. The detailed procedures were described in the Appendix S1.
| Colony formation assay
Five hundred cells were cultured in a 6-well plate for 10 days. The clones were treated with 4% paraformaldehyde and 0.05% crystal violet. The clones were counted via Image J. 
| Cell migration and scratch assays
| Cell apoptosis assay
Cells apoptosis was assessed by Annexin V-APC/PI apoptosis kits (AntGent, China). Cells were collected and then washed with PBS twice. APC and PI were added in the dark room and incubated for 15 minutes. The apoptosis rate was detected by flow cytometry.
| IHC
The detailed procedures for IHC were described in the Appendix S1.
| Transfection assay
The detailed procedures for transfection assay were described in the Appendix S1.
| Real-time PCR
The detailed procedures were described in the Appendix S1. The primer sequences were provided in Table S1 .
| Animal experiments
The detailed procedures for Animal experiments were described in the Appendix S1.
| Chromatin immunoprecipitation
The detailed procedures for chromatin immunoprecipitation (ChIP)
were described in the Appendix S1.
| Luciferase reporter assays
The detailed procedures for Luciferase reporter assay were described in the Appendix S1.
F I G U R E 5 NFIB silencing inhibits EMT and CyclinD1 and Bcl-2 expression in colorectal cancer cells. *P < 0.05. NFIB, nuclear factor I/B
| Statistical analysis
Unpaired t tests were used to test the difference between groups. The expression of NFIB in 54 CRC tissues and paired adjacent noncancerous tissues was analyzed using the paired t test.
The relationships between the expression of NFIB and clinical characteristics of CRC were analyzed by the χ 2 test. P value <0.05 was considered statistically significant, and all statistical tests were two-sided. All assays were repeated at least three times. The statistical analysis was carried out using GraphPad Prism5.0. The data were presented as the mean ± standard deviation (SD).
F I G U R E 6 Nuclear factor I/B (NFIB) induces EMT by upregulating Snail in CRC cells. A, Snail protein and mRNA were overexpressed after transfection of Snail cDNA. B-C, Snail overexpression partially restored EMT, which was inhibited by NFIB knockdown. D-E, Scratch assays (magnification, ×40) and transwell assays (magnification, ×200) showed that snail overexpression promoted cell migration, which was impaired by NFIB knockdown. *P < 0.05. CRC, colorectal cancer
| RE SULTS
| NFIB is overexpressed in CRC tissues
We analyzed the expression of NFIB mRNA from the Oncomine database and discovered that the expression of NFIB in tumor tissues was significantly higher than that in paracancerous tissues in some date-sets (data not shown). In most CRC types, NFIB was significantly overexpressed in the cancer tissues ( Figure 1A-H) .
Next, to determine the diagnostic value of NFIB expression in CRC,
we plotted the ROC curve according to NFIB expression in cancer tissues and corresponding paracancerous tissues provided by TCGA website. The area under the curve (AUC) was 0.8280 (95% CI: 0.7512-0.9409; P < 0.0001), with a sensitivity of 75.00% and a specificity of 78.85% at the cutoff value, which showed that NFIB could clearly distinguish CRC tissues from paracancerous tissues ( Figure 1I ). In addition, NFIB mRNA expression in the subgroups of CRC patients was determined by ROC curve analysis, and the (Table 1) .
| NFIB promotes tumorigenesis of CRC cells in vivo
To further explore the effects of NFIB on CRC tumorigenesis, we transfected sh-NFIB into SW480 and DLD1 cells, and NFIB cDNA was transfected into LoVo cells using a lentiviral vector. The expression of NFIB mRNA and protein was knocked down by sh-NFIB and overexpressed by NFIB cDNA ( Figure 3A and Figure S1A ). We discovered that NFIB silencing significantly reduced the volume of subcutaneous xenograft tumors and that NFIB overexpression promoted subcutaneous xenograft tumor growth ( Figure 3B and Figure S1B ). Moreover, the IHC results showed that the proliferation marker Ki-67 index was decreased and apoptotic TUNEL staining was increased in the SW480-sh-NFIB groups in vivo ( Figure 3C ).
In contrast, the Ki-67 index was increased, and TUNEL staining was decreased in the LoVo-NFIB groups ( Figure S1C ). These results indicated that NFIB promoted xenograft tumor growth by enhancing cell proliferation and inhibiting cell apoptosis.
| NFIB promotes cell growth, colony formation, and migration and decreases sensitivity to 5-FU
In vivo, we found that NFIB played an oncogenic role in CRC cells. To Taken together, the results showed that NFIB played a role as an oncogene in CRC by promoting CRC cell proliferation, migration and 5-FU resistance.
| NFIB induces the EMT profile and upregulates the expression of Bcl-2 and CyclinD1 in CRC cells
Epithelial-mesenchymal transition is an important mechanism of migration and metastasis. Therefore, the expression levels of the EMT-related transcription factors (EMT-TF) Zeb1, Zeb2, Twist, Slug and Snail were detected by RT-PCR, and the results revealed that NFIB could promote Snail expression ( Figure S3 and Figure 5 ). NFIB knockdown decreased the expression of Snail and Vimentin, whereas E-cadherin and Zo-1 were increased both in SW480 cells and DLD1 cells ( Figure 5 ). Coincidently, NFIB overexpression increased the expression of Snail and Vimentin and decreased the expression of E-cadherin and Zo-1 ( Figure S3 ).
Bcl-2 and CyclinD1 are involved in tumor cell proliferation by
regulating cell apoptosis and the cell cycle. We discovered that the expression of Bcl-2 and CyclinD1 in NFIB knockdown cells was decreased ( Figure 5 ). In contrast, NFIB overexpression significantly increased Bcl-2 and CyclinD1 expression in LoVo cells ( Figure S3 ).
| NFIB induces EMT by upregulating Snail expression
In our study, we found that NFIB induced EMT and upregulated the expression of Snail. As an important EMT-TF, Snail governs EMT.
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To explore the functions of Snail in NFIB-induced EMT, we trans- F I G U R E 9 Nuclear factor I/B (NFIB) silencing affects cell proliferation, apoptosis and 5-FU sensitivity via inactivating the Akt signaling pathway. A, CCK8 assays indicated that SC-79 (5 μg/mL) could increase cell proliferation in colorectal cancer (CRC) cells, which was impaired by NFIB knockdown. B, Apoptosis results showed that NFIB regulated apoptosis by the Akt signaling pathway. The concentration of SC-79 was 5 μg/mL, and 0.1% DMSO vehicle was selected as the control. C, The 5-FU sensitivity curve showed that SC-79 pretreatment (5 μg/mL, 2 hours) obviously decreased the 5-FU sensitivity compared with that of NFIB knockdown cells pretreated with 0.1% DMSO vehicle in CRC. *P < 0.05, **P < 0.01
| NFIB promotes Snail transcription by binding to the Snail promoter
The Snail promoter region was searched on the ROMO website (http://alggen.lsi.upc.es), and we discovered that there were two potential binding sites for NFIB ( Figure 7A ). The two potential binding sites were named potential binding site 1# (1#) and potential binding site 2# (2#). Next, ChIP assays were performed in SW480, DLD1 and LoVo cells using NFIB antibodies (NFIB). Compared to the sample bound to IgG, the NFIB-bound complex showed a remarkable enrichment of 1# of the snail promoter ( Figure 7B and Figure S5 ). To further confirm that the binding of NFIB to the Snail promoter is functional, we performed a luciferase reporter assay of 293T cells.
The NFIB overexpression group showed substantially increased luciferase activities of the wild-type snail promoter-containing pGL3
reporter vector (Snail-WT) and the 2# mut Snail promoter-containing pGL3 reporter vector (Snail-2#-mut) but not the 1# mut or 1#2# mut Snail promoter-containing pGL3 reporter vectors (Snail-1# mut and 2# mut) when compared with the negative control (vector) group ( Figure 7C ). These results indicated that NFIB binded to 1# and promoted Snail transcription.
| NFIB increases cell proliferation and decreases cell apoptosis and sensitivity to 5-FU by activating the Akt signaling pathway
The Akt signaling pathway has been proved to be an important mechanism to regulate apoptosis and proliferation in many types of tumors. In our study, we discovered that the p-Akt level was decreased in NFIB knockdown cells and increased in NFIB overexpression cells ( Figure 8A and Figure S6A ). The Akt activator SC-79 was used to abolish this inhibitory effect of NFIB knockdown. We discovered Table 2 ). MK-2206 pretreatment also increased cell apoptosis ( Figure S6F ). In conclusion, NFIB promoted cell proliferation and inhibited cell apoptosis and 5-FU sensitivity by activating the Akt signaling pathway. (MMPs). [21] [22] [23] Our study demonstrated that NFIB induced EMT by upregulating snail expression.
| D ISCUSS I ON
The Akt signaling pathway plays an important role in cell processes, including cell proliferation, differentiation, apoptosis and drug resistance. 24 Activation of Akt is a "common approach" for many intracellular and extracellular signaling molecules to promote survival and proliferation. Activation of the Akt pathway can alleviate the tumor cell damage caused by chemotherapeutic drugs by enhancing DNA repair and inducing the expression of drug pump proteins. [25] [26] [27] [28] NFIB was reported to bind to the EZH2 promoter and promote EZH2 expression, 9 which could activate the PI3K/AKT pathway. 10 Wu et al 11 discovered that NFIB can activate the Akt/ Stat3 signaling pathway in gastric cancer. However, the relationship between the effects of NFIB on the biological behavior of CRC and the activation of the Akt pathway has not been reported. In our study, we discovered that NFIB promoted cell proliferation and 5-FU insensitivity by activating the Akt pathway.
We also discovered that NFIB weakened 5-FU sensitivity. The mechanism of chemotherapeutic resistance is very complicated, and three important mechanisms are widely recognized. First, drug efflux proteins, especially the ATP-binding cassette (ABC)
transporter family of proteins, play a key role in chemotherapeutic resistance. 29 Second, DNA repair pathways, a defense mechanism, are essential to maintain DNA integrity and resist chemotherapeutic damage. 30 Third, activation of the anti-apoptotic pathway and expression of anti-apoptotic proteins are also an important mechanism of chemotherapeutic resistance. 31 The PI3K/Akt pathway and Bcl-2 protein are important components that can promote cancer cell survival. 31 In our study, we revealed that NFIB promoted Akt pathway activation and upregulated Bcl-2 expression in CRC cells. Furthermore, the link between EMT and cancer cell drug resistance has been known for many decades. 32 In the EMT process, cells show stem cell characteristics and upregulate drug efflux protein. 33 In addition, Saxena et al 34 discover that the activity of EMT-TF binding to the promoter of ABC transporters is increased. In our study, NFIB-induced CRC cell EMT could partially explain how NFIB causes 5-FU insensitivity.
In conclusion, our results revealed that NFIB promoted cell migration and proliferation while inhibited CRC cell apoptosis and 5-FU
sensitivity. Subsequently, we demonstrated that NFIB induced EMT by upregulating snail expression and promoted cell proliferation and 5-FU resistance by activating the Akt signaling pathway, which suggested that NFIB might be an important therapeutic target for the treatment of CRC.
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